Risankizumab Efficacy and Safety Based on Prior Inadequate Response or Intolerance to Advanced Therapy: Post Hoc Analysis of the INSPIRE and COMMAND Phase 3 Studies.
Panaccione R, Louis E, Colombel JF, D'Haens G, Peyrin-Biroulet L, Dubinsky M, Takeuchi K, Rubin DT, Kalabic J, Chien KB, Chen S, Cheng L, Zhang Y, Duan WR, Vladea R, Hecht PM, Morisset P, Schreiber S, Ferrante M.
Panaccione R, et al. Among authors: zhang y.
J Crohns Colitis. 2025 Jan 13:jjaf005. doi: 10.1093/ecco-jcc/jjaf005. Online ahead of print.
J Crohns Colitis. 2025.
PMID: 39804294